Chat with us, powered by LiveChat

Nuclear Imaging Device Market (Product Type - Positron Emission Computed Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Planar Scintigraphy, and Hybrid Systems; Application - Oncology, Cardiology, Neurology, Orthopedics, and Others; End User - Hospitals, Diagnostic Imaging Centers, Research Institutes, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Nuclear Imaging Device Market (Product Type - Positron Emission Computed Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Planar Scintigraphy, and Hybrid Systems; Application - Oncology, Cardiology, Neurology, Orthopedics, and Others; End User - Hospitals, Diagnostic Imaging Centers, Research Institutes, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01215 Category: Healthcare & Medical Devices Published: August, 2023

A recent report published by Infinium Global Research on nuclear imaging device market provides in-depth analysis of segments and sub-segments in the global as well as regional nuclear imaging device market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional nuclear imaging device market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global nuclear imaging device market.

Market Insight:

The global nuclear imaging device market was valued at USD 2.75 billion in 2022 and is expected to reach USD 4.56 billion in 2030, with a CAGR of 5.71% during the forecast period 2023-2030.

Nuclear imaging device represent a crucial and advanced frontier in modern medical diagnostics. By utilizing radioactive tracers or radiopharmaceuticals, these cutting-edge imaging systems provide valuable insights into the body's internal structures and metabolic processes. Through a combination of functional and anatomical information, nuclear imaging plays a vital role in diagnosing, staging, and monitoring various medical conditions. From oncology to cardiology, neurology, and beyond, these device have found widespread applications in multiple medical specialties, contributing to early disease detection and effective treatment planning. In this era of ever-evolving healthcare technology, nuclear imaging device continue to revolutionize medical imaging, offering non-invasive and safe procedures that enhance patient care and improve clinical outcomes.

The market for nuclear imaging device is driven by the rising prevalence of cancer, cardiovascular diseases, and neurological disorders is a significant factor contributing to the increased demand for nuclear imaging device in the healthcare industry. As these diseases become more prevalent globally, there is a growing demand for advanced diagnostic tools that can provide accurate and timely information to aid in their early detection and effective treatment. The government of different countries such as India, China, the U.S., Canada, and others are effectively allocating budgets for healthcare expenditures which motivates the manufacturers of the medical industry. According to the Centers for Medicare & Medicaid Services, “In 2020, the U.S. health care spending reached $4,124.0 billion, an increase of 9.7% compared to 2019”. This equates to an average of $12,530 per person in the country.” Positron Emission Computed Tomography (PET) is expected to maintain its dominance in the nuclear imaging device market based on product type in 2023. This is due to the widespread adoption of PET for its ability to provide functional information on metabolic processes in the body, which is critical in cancer management. The high sensitivity and specificity of PET in cancer diagnosis, staging, and treatment monitoring contribute to its significant role in oncology. The increasing global prevalence of cancer and the growing emphasis on personalized medicine are driving the demand for PET imaging device.

Nuclear Imaging Device Market Size, Share, Trends | IGR

The global nuclear imaging device market is segmented into Asia Pacific, North America, Europe, the Middle East & Africa, and South America. Among the regions, the nuclear imaging device market is anticipated to be dominated by North America, with the highest CAGR during the forecast period. The United States is anticipated to have a significant market share, exceeding 29% of the total value. The high growth in this region can be attributed to factors such as the presence of prominent manufacturers of nuclear imaging device in this region, increased government spending on the healthcare sector, rising incidence of chronic diseases, growing awareness of the benefits of early disease diagnosis, and healthcare system improvements. The healthcare market in the Asia Pacific is experiencing unprecedented growth, driven by factors such as higher healthcare costs, an aging demographic, a rise in chronic diseases, and a growing population of discerning healthcare consumers. According to the Asia Pacific Medical Technology Association Ltd., “The APAC MedTech industry's value is projected to reach US$ 157 billion by 2022, with a remarkable Compound Annual Growth Rate (CAGR) of 8.8%”.

Report Scope of the Nuclear Imaging Device Market:

Report Coverage Details
Market Size in 2022 USD 2.75 Billion
Market Size by 2030 USD 4.56 Billion
Growth Rate from 2023 to 2030 CAGR of 5.71%
Largest Market North America
No. of Pages 255
Market Drivers
  • The rising prevalence of cancer, cardiovascular diseases, and neurological disorders fuels the demand for nuclear imaging devices. These devices play a crucial role in early diagnosis and effective treatment planning.

  • Rising healthcare expenditure across the globe is driving the market growth.

Market Segmentation By Product Type, By Application, and By End User
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global nuclear imaging device market covers segments such as product type, application, and end user. On the basis of product type, the sub-markets include positron emission computed tomography (PET), single photon emission computed tomography (SPECT), planar scintigraphy, and hybrid systems. On the basis of application, the sub-markets include oncology, cardiology, neurology, orthopedics, and others. On the basis of end user, the sub-markets include hospitals, diagnostic imaging centers, research institutes, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Siemens Healthcare GmbH, GE HealthCare, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Mediso Ltd., DIGIRAD HEALTH, INC., SurgicEye GmbH, Spectrum Dynamics Medical, DDD-Diagnostic A/S, and CMR Naviscan.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the nuclear imaging device market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global nuclear imaging device market was valued at USD 2.75 Billion in 2022.
It is likely to grow at a CAGR of 5.71% during the forecast period 2023-2030.
The global nuclear imaging device market is estimated to reach USD 4.56 Billion by the end of 2030.
North America is anticipated to exhibit high demand for nuclear imaging device market during the forecast period.
Siemens Healthcare GmbH, GE HealthCare, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Mediso Ltd., DIGIRAD HEALTH, INC., SurgicEye GmbH, Spectrum Dynamics Medical, DDD-Diagnostic A/S, and CMR Naviscan.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.